Bracco

  
Bracco’s Isovue (iopamidol injection) 
Bracco (Booth 2845) is introducing its new solutions in diagnostic imaging. On the heels of its acquisition of E-Z-EM, Bracco is broadening its footprint in the radiology environment as it unveils its new expanded product portfolio.  

Bracco—along with ACIST Medical Systems—offers a rich and diverse portfolio of products, including imaging agents and delivery systems that meet the needs of virtually all key diagnostic imaging modalities. The company is showcasing Gastrografin (diatrizoate meglumine and diatrizoate sodium solution USP), a palatable lemon-flavored, water-soluble iodinated radiopaque contrast medium for oral or rectal administration used for radiographic examination of segments of the gastrointestinal tract and as an adjunct to contrast enhancement in CT of the torso. Also being highlighted is Isovue (iopamidol injection), a safe and effective nonionic contrast medium well established with U.S. clinical experience since 1986 that is indicated for a wide variety of radiological procedures.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.